Monitor for actual execution of the sale via future Form 4 filings; given the officer status and recent pattern of insider selling, this may signal routine portfolio management rather than negative sentiment. However, traders should watch for cumulative insider outflows over time.
Price Chart
Executive Summary
Fady Malik, an officer at Cytokinetics, filed a Form 144 to notify intent to sell 22,000 shares of common stock, valued at approximately $1.43 million, acquired through stock option exercises. The filing is a routine notice of planned sales under Rule 144, with no indication of immediate market impact or unusual activity.
Key Facts
- Fady Malik, an officer of Cytokinetics, filed Form 144 to sell up to 22,000 shares.
- The shares are to be sold on the NASDAQ, with an approximate value of $1.43 million based on current market prices.
- Shares were acquired through the exercise of stock options on March 9 and March 17, 2026, and will be sold for cash.
- This is an advance notice of intent to sell; actual sale may not occur immediately or at all.
- Recent insider activity shows $2.9M in insider sells over the past 30 days, indicating ongoing routine selling.
Financial Impact
$1.43 million in potential share sales (22,000 shares), representing a small fraction of the company's $8.0B market cap.
Risk Factors
- Potential downward price pressure if the full 22,000 shares are sold quickly.
- Perception of insider pessimism if combined with other negative catalysts, though standalone impact is minimal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003289 |
| Document: 0001950047-26-003289-index.html | 0001950047-26-003289 |
| Document: 0001950047-26-003289.txt | 0001950047-26-003289 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access